Dr. Idoroenyi Amanam, MD

Dr. Amanam practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Amanam's NPI, 1205257920, was assigned on December 23, 2013. Dr. Amanam graduated from Meharry Medical College School of Medicine in 2022. Dr. Amanam holds California license A131624.

Dr. Amanam's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Amanam's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Amanam to 1 more other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amanam practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Amanam's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Amanam is board certified in hematology by the American Board of Internal Medicine. Dr. Amanam is licensed in California.

Dmand AI lists anemia, chronic anemia, chronic leukemia, deep vein thrombosis (DVT), immune deficiency disease and purpura and thrombocytopenia among the conditions Dr. Amanam treats.

CMS data shows 782 Medicare services from Dr. Amanam across 7 procedure codes in 2024, for 210 Medicare patients. Medicare paid $72,798 for them.

CMS counts 210 Medicare patients who saw Dr. Amanam in 2024. The largest group is 65 to 74, with 98 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amanam's median patient age at 66, with 49% women.

In 2024, Dr. Amanam wrote 111 Medicare Part D claims for 32 patients. 64% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $24 in total drug cost. In 2020, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Amanam for performance year 2024, reported as part of a group. Dr. Amanam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Amanam as offering telehealth.

Dmand AI links 42 papers to Dr. Amanam, published from 2015 to 2025. 2024 was the busiest year, with 8. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Transplantation Conditioning. Dr. Amanam has published most often in Bone Marrow Transplant. Dr. Amanam's most frequent co-authors are Ryotaro Nakamura, MD, Amandeep Salhotra, MD and Haris Ali, MD.

Dmand AI links Dr. Amanam to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute and Leukemia, Myeloid. Open Payments lists research payments to Dr. Amanam that name 1 trial.

CMS Open Payments shows 149 general payments to Dr. Amanam from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Incyte Corporation paid the most, $14,280. It also lists 1 research payment totaling $21 in 2022, naming 1 clinical trial.

Dr. Amanam graduated from Meharry Medical College School of Medicine in 2022.

Dr. Amanam is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.